Metastatic Colorectal Cancer: Telisotuzumab Adizutecan Study

We are investigating a new treatment combination for people with metastatic colorectal cancer to see if it works better and is safer than current standard treatments.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Bevacizumab
Bevacizumab is a substance that blocks formation of new blood vessels to treat certain cancers and eye conditions caused by abnormal vessel growth.
Fluorouracil
Fluorouracil is a substance used to treat cancer by stopping the growth of cancer cells.
Folinic Acid
Folinic acid is a substance that helps restore folate levels and protects healthy cells during certain chemotherapy treatments.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Telisotuzumab

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Medical University Of Graz
Department of Internal Medicine, Division of Oncology
Graz, Austria
SCRI CCCIT Ges.m.b.H.
3rd Medical Department with Hematology, Medical Oncology, Hemostaseology, Infectious Disease
Salzburg, Austria
Medical University Of Vienna
Department of Medicine Division of Oncology
Vienna, Austria

Sponsor: AbbVie Deutschland GmbH & Co. KG
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.